Join me in ep 10 as I interviewed co-founder and CEO of Oxford Nanopore, Gordon Sanghera, and SVP of Population Health & Precision Medicine, Kathleen Barnes, during their visit to Singapore earlier this week.

(0:00) Introduction (1:42) About Oxford Nanopore (3:51) Applications in agriculture, food & environment (5:11) Collaboration with Ministry of Health Singapore (6:52) Collaboration with local ecosystem (11:27) Challenges and opportunities in Southeast Asia

Oxford Nanopore was founded in 2005 as a spin-out from the University of Oxford. They developed the world’s first and only nanopore DNA and RNA sequencing platform — that offers scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data.

Dr Gordon Sanghera is co-founder and CEO of Oxford Nanopore. He has led the company through multiple finance rounds, and in 2021, a listing on the London Stock Exchange.

Kathleen Barnes is the SVP of Population Health & Precision Medicine at Oxford Nanopore. Kathleen’s career spans >30 years focused on genomic medicine and precision-driven health equity.

Subscribe now for more engaging discussions at the intersection of technology and healthcare. Stay curious, stay inspired, and delve into the world of #Medtech & #Biotech with us! #precisionmedicine #precisionmedicine #deepmedtech #Medicalpodcast #Southeastasia #SEA #Medtechpodcast